Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis

Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of trans...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacokinetics Vol. 57; no. 4; pp. 491 - 503
Main Authors Li, Rui, Barton, Hugh A.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.04.2018
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0312-5963
1179-1926
1179-1926
DOI10.1007/s40262-017-0568-7

Cover

Loading…
Abstract Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates. Objective The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations. Methods We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects. Results Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations. Conclusion This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics.
AbstractList Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates.Objective The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations.Methods We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects.Results Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations.Conclusion This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics.
Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates. Objective The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations. Methods We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects. Results Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations. Conclusion This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics.
Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates. The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations. We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects. Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations. This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics.
Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates.BACKGROUNDEthnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an intrinsic ethnic variability in transporter activity, allele frequencies of transporters cannot explain observed ethnic variability in pharmacokinetics. However, this hypothesis contradicts the data collected from compounds that are OATP1B1 substrates but not breast cancer resistance protein (BCRP) substrates.The objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations.OBJECTIVEThe objective of this study is to evaluate a hypothesis that is physiologically reasonable and more consistent with clinical observations.We evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects.METHODSWe evaluated if allele frequencies of two transporters (OATP1B1 and BCRP) are key contributors to ethnic variability. In this hypothesis, the same genotype leads to the same activity independent of ethnicity, in contrast to the previous hypothesis of intrinsic ethnic variability in OATP1B1 activity. As a validation, we perform mechanistic pharmacokinetic modeling for SLCO1B1 (encoding OATP1B1) and ABCG2 (encoding BCRP) genotyped pharmacokinetic data from 18 clinical studies with healthy Caucasian and/or Asian subjects.Simulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations.RESULTSSimulations based on the current hypothesis reasonably describe SLCO1B1 and ABCG2 genotyped pharmacokinetic time course data for five transporter substrates (atorvastatin, pitavastatin, pravastatin, repaglinide, and rosuvastatin) in Caucasian and Asian populations.This hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics.CONCLUSIONThis hypothesis covers the observations that can (e.g., ethnic differences in rosuvastatin pharmacokinetics) or cannot (e.g., lack of differences for pitavastatin pharmacokinetics) be explained by the previous hypothesis. It helps to characterize sources of ethnic variability and provides a foundation for predicting ethnic variability in transporter substrate pharmacokinetics.
Author Barton, Hugh A.
Li, Rui
Author_xml – sequence: 1
  givenname: Rui
  orcidid: 0000-0003-1825-2401
  surname: Li
  fullname: Li, Rui
  email: Rui.Li5@pfizer.com
  organization: Systems Modeling and Simulation, Medicine Design, World Wide Research and Development, Pfizer Inc
– sequence: 2
  givenname: Hugh A.
  surname: Barton
  fullname: Barton, Hugh A.
  organization: Translational Modeling and Simulation, Biomedicine Design, World Wide Research and Development, Pfizer Inc
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28653144$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1uEzEUhUeoiKaFB2CDLLFhM2B7PD9mgTSNUorUqhEEttYdx8k4OHawPUDejYfD05QClWBlWT7fveden5PsyDqrsuwpwS8JxvWrwDCtaI5JneOyavL6QTYhpOY54bQ6yia4IDQveVUcZychbDDGDcX4UXZMm6osCGOT7Mfs-86Attqu0Sz2Vkv0CbyGThsd98it0MKDDTvno_Low9CF6CEqNO_Bb0G6z9qqqGVA2qILBSb2e9QGDRaBXaIpDBJuboncKBkD-qZjj1pjlFHo3Ksvg7JSqzB2um4Xc3JGbsiz6fv5a9SiKyV7sDqkHujKLZUZjbYWzD7o8Dh7uAIT1JPb8zT7eD5bTC_yy-u376btZS5ZjWPOKCeMpA3VDWcVpOUwSqFsmqrugHFJqqIs66ImlPGmY6A4rxhfqY4sy6JUuDjN3hzq7oZuq5ZS2bQEI3Zeb8HvhQMt_n6xuhdr91WUTfoWTlOBF7cFvEsThyi2OkhlDFjlhiBIMkgbzkmZpM_vSTdu8GngICjBnDaYUJJUz_50dGfl18cmATkIpHcheLW6kxAsxvCIQ3hECo8YwyPqxNT3GKkjRO3GobT5L0kPZEhd7Fr536b_Df0EPHnY2A
CitedBy_id crossref_primary_10_1007_s40262_020_00876_0
crossref_primary_10_1007_s11883_017_0701_y
crossref_primary_10_1080_17425255_2021_1998455
crossref_primary_10_1016_j_ejps_2020_105280
crossref_primary_10_1002_jcph_1105
crossref_primary_10_1080_00498254_2019_1708514
crossref_primary_10_3390_ijms22062786
crossref_primary_10_1080_03602532_2024_2399523
crossref_primary_10_2174_1574884714666190408125206
crossref_primary_10_1007_s11095_021_03109_6
crossref_primary_10_1208_s12248_019_0337_7
crossref_primary_10_1007_s12272_023_01476_9
crossref_primary_10_1002_cpdd_1157
crossref_primary_10_1002_psp4_12582
crossref_primary_10_1002_cpdd_1044
crossref_primary_10_1124_dmd_118_083030
crossref_primary_10_1080_17425255_2020_1749595
crossref_primary_10_1124_dmd_118_084988
crossref_primary_10_3389_fphar_2021_698966
crossref_primary_10_1080_17425255_2023_2202813
crossref_primary_10_3390_ph17111411
crossref_primary_10_1002_prp2_890
Cites_doi 10.1007/s00228-014-1800-0
10.1097/01.fpc.0000114750.08559.32
10.1038/clpt.2009.181
10.1124/pr.110.002857
10.1007/s11222-006-9438-0
10.2165/00003088-200342130-00005
10.1007/s10928-014-9357-1
10.1124/jpet.115.225045
10.1016/S0149-2918(03)80316-8
10.1158/1078-0432.CCR-04-0144
10.1097/00008571-200301000-00004
10.3389/fphar.2011.00041
10.1097/01.fpc.0000230422.50962.91
10.2165/11592480-000000000-00000
10.1038/sj.clpt.6100190
10.1124/dmd.104.001628
10.2133/dmpk.DMPK-12-RG-068
10.1016/S0009-9236(03)00060-2
10.1038/clpt.2012.221
10.1177/0091270002239702
10.1097/FPC.0b013e3282fb02a3
10.1002/jps.20502
10.1038/psp.2014.50
10.3109/00498254.2010.523736
10.1111/bcp.12377
10.2133/dmpk.DMPK-11-RV-099
10.1111/j.1365-2125.1990.tb03626.x
10.1007/s00228-006-0123-1
10.1124/dmd.115.063362
10.1016/j.clpt.2005.06.013
10.1097/FPC.0b013e3280ef698f
10.1016/j.clpt.2006.06.010
10.1007/s00228-014-1801-z
10.1111/j.1365-2710.2009.01127.x
10.1002/ijc.11669
10.1038/sj.clpt.6100267
10.1007/s10928-011-9232-2
10.1517/17425250902976854
10.1038/clpt.2009.79
10.1038/sj.clpt.6100220
ContentType Journal Article
Copyright The Author(s) 2017
Copyright Springer Science & Business Media Apr 2018
Copyright_xml – notice: The Author(s) 2017
– notice: Copyright Springer Science & Business Media Apr 2018
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
4T-
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1007/s40262-017-0568-7
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Docstoc
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Docstoc
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1179-1926
EndPage 503
ExternalDocumentID PMC5856892
28653144
10_1007_s40262_017_0568_7
Genre Journal Article
GroupedDBID ---
-5G
-BR
-EM
.GJ
.XZ
0R~
0VX
199
29B
2JY
34G
36B
39C
3V.
4.4
406
53G
5GY
5RE
6I2
6J9
6PF
7X7
88E
8FI
8FJ
8R4
8R5
8UJ
95.
AAAUJ
AABHQ
AACDK
AADNT
AAIAL
AAIKX
AAJKR
AAKAS
AANZL
AARHV
AASML
AATNV
AAWTL
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABFTV
ABIPD
ABJNI
ABJOX
ABKCH
ABKMS
ABKTR
ABOCM
ABPLI
ABTKH
ABTMW
ABUWG
ABWHX
ABXPI
ACAOD
ACCOQ
ACCUX
ACDTI
ACGFO
ACGFS
ACMJI
ACMLO
ACOKC
ACPIV
ACREN
ACZOJ
ADBBV
ADFRT
ADFZG
ADHHG
ADJJI
ADQRH
ADRFC
ADURQ
ADYOE
ADZCM
ADZKW
AEBTG
AEFQL
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AEVLU
AEXYK
AEYRQ
AFALF
AFBBN
AFFNX
AFKRA
AFWTZ
AFZKB
AGAYW
AGDGC
AGQEE
AGQMX
AGRTI
AHIZS
AHMBA
AHSBF
AIAKS
AIGIU
AILAN
AIZAD
AJRNO
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
ASPBG
AVWKF
AWSVR
AXYYD
AZFZN
A~4
BENPR
BGNMA
BPHCQ
BVXVI
BYPQX
C6C
CAG
CCPQU
COF
CS3
DCUDU
DNIVK
DPUIP
DU5
EBLON
EBS
EJD
EMOBN
ESX
F5P
F8P
FERAY
FIGPU
FLLZZ
FNLPD
FSGXE
FYUFA
HF~
HMCUK
IAO
IEA
IHR
IMOTQ
INH
INR
ITC
IWAJR
J-C
JZLTJ
LGEZI
LLZTM
LOTEE
M1P
M4Y
NADUK
NQJWS
NU0
NXXTH
OAC
OPC
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
ROL
RSV
RZALA
SISQX
SJYHP
SNPRN
SNX
SOHCF
SOJ
SPKJE
SRMVM
SSLCW
TEORI
TSG
U5U
U9L
UAX
UG4
UKHRP
UNMZH
UTJUX
VDBLX
VFIZW
W48
WAF
YQY
Z0Y
Z7U
ZGI
ZMTXR
ZXP
~JE
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
4T-
7XB
8FK
ABRTQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c470t-42914105678946a192422a58867ba49c1635573712498b4ae99649feb1d535e03
IEDL.DBID C6C
ISSN 0312-5963
1179-1926
IngestDate Thu Aug 21 14:13:09 EDT 2025
Tue Aug 05 10:38:24 EDT 2025
Fri Jul 25 05:04:28 EDT 2025
Thu Apr 03 06:58:33 EDT 2025
Thu Apr 24 22:55:02 EDT 2025
Tue Jul 01 01:31:33 EDT 2025
Fri Feb 21 02:27:38 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c470t-42914105678946a192422a58867ba49c1635573712498b4ae99649feb1d535e03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1825-2401
OpenAccessLink https://doi.org/10.1007/s40262-017-0568-7
PMID 28653144
PQID 2109280121
PQPubID 32335
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5856892
proquest_miscellaneous_1914289915
proquest_journals_2109280121
pubmed_primary_28653144
crossref_primary_10_1007_s40262_017_0568_7
crossref_citationtrail_10_1007_s40262_017_0568_7
springer_journals_10_1007_s40262_017_0568_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-04-01
PublicationDateYYYYMMDD 2018-04-01
PublicationDate_xml – month: 04
  year: 2018
  text: 2018-04-01
  day: 01
PublicationDecade 2010
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: Switzerland
– name: Auckland
PublicationTitle Clinical pharmacokinetics
PublicationTitleAbbrev Clin Pharmacokinet
PublicationTitleAlternate Clin Pharmacokinet
PublicationYear 2018
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References Niemi, Pasanen, Neuvonen (CR1) 2011; 63
Ieiri, Higuchi, Sugiyama (CR22) 2009; 5
Niemi (CR24) 2004; 14
Haario (CR15) 2006; 16
Kim, Joo, Park (CR31) 2010; 35
Keskitalo (CR7) 2009; 86
Singhvi (CR12) 1990; 29
Pasanen (CR38) 2006; 62
Martin (CR11) 2003; 25
Li (CR6) 2014; 41
Choi (CR43) 2008; 83
Sui (CR39) 2011; 46
Birmingham (CR30) 2015; 71
Wan (CR8) 2015; 354
Ieiri (CR18) 2007; 82
Lee (CR40) 2005; 78
Li, Barton, Maurer (CR20) 2014; 3
Mizuarai, Aozasa, Kotani (CR34) 2004; 109
Birmingham (CR13) 2015; 71
Deng (CR26) 2008; 18
Ho (CR23) 2007; 17
Warrington, Nagakawa, Hounslow (CR5) 2011; 31
Rodgers, Rowland (CR10) 2006; 95
Imai (CR36) 2002; 1
Peng (CR3) 2015; 43
Choi (CR25) 2011; 41
Oh (CR17) 2013; 28
Riedmaier (CR28) 2011; 2
Nakanishi, Tamai (CR32) 2012; 27
Kobayashi (CR37) 2005; 33
Riedmaier (CR29) 2010; 87
Pasanen (CR16) 2007; 82
Niemi (CR21) 2006; 16
Thomsen (CR4) 2003; 43
Zhu (CR41) 2013; 26
Tomita, Maeda, Sugiyama (CR2) 2013; 94
de Jong (CR33) 2004; 10
Prueksaritanont (CR19) 2014; 78
Shah, Betts (CR9) 2012; 39
Lennernas (CR14) 2003; 42
Zamber (CR35) 2003; 13
Niemi, Pasanen, Neuvonen (CR27) 2006; 80
Nishizato (CR42) 2003; 73
MK Pasanen (568_CR38) 2006; 62
KA Kim (568_CR31) 2010; 35
FA Jong de (568_CR33) 2004; 10
I Ieiri (568_CR22) 2009; 5
S Warrington (568_CR5) 2011; 31
JE Keskitalo (568_CR7) 2009; 86
H Haario (568_CR15) 2006; 16
T Prueksaritanont (568_CR19) 2014; 78
R Li (568_CR20) 2014; 3
D Kobayashi (568_CR37) 2005; 33
SM Sui (568_CR39) 2011; 46
PD Martin (568_CR11) 2003; 25
RH Ho (568_CR23) 2007; 17
JW Deng (568_CR26) 2008; 18
JH Choi (568_CR43) 2008; 83
T Nakanishi (568_CR32) 2012; 27
DK Shah (568_CR9) 2012; 39
Y Tomita (568_CR2) 2013; 94
SM Singhvi (568_CR12) 1990; 29
I Ieiri (568_CR18) 2007; 82
M Niemi (568_CR1) 2011; 63
MK Choi (568_CR25) 2011; 41
BK Birmingham (568_CR13) 2015; 71
Y Nishizato (568_CR42) 2003; 73
KW Peng (568_CR3) 2015; 43
H Lennernas (568_CR14) 2003; 42
MK Pasanen (568_CR16) 2007; 82
MS Thomsen (568_CR4) 2003; 43
Z Wan (568_CR8) 2015; 354
J Zhu (568_CR41) 2013; 26
M Niemi (568_CR27) 2006; 80
CP Zamber (568_CR35) 2003; 13
M Niemi (568_CR24) 2004; 14
ES Oh (568_CR17) 2013; 28
E Lee (568_CR40) 2005; 78
BK Birmingham (568_CR30) 2015; 71
R Li (568_CR6) 2014; 41
S Riedmaier (568_CR29) 2010; 87
Y Imai (568_CR36) 2002; 1
S Mizuarai (568_CR34) 2004; 109
T Rodgers (568_CR10) 2006; 95
M Niemi (568_CR21) 2006; 16
S Riedmaier (568_CR28) 2011; 2
References_xml – volume: 71
  start-page: 329
  issue: 3
  year: 2015
  end-page: 340
  ident: CR13
  article-title: Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-014-1800-0
– volume: 14
  start-page: 429
  issue: 7
  year: 2004
  end-page: 440
  ident: CR24
  article-title: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
  publication-title: Pharmacogenetics
  doi: 10.1097/01.fpc.0000114750.08559.32
– volume: 87
  start-page: 65
  issue: 1
  year: 2010
  end-page: 73
  ident: CR29
  article-title: UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2009.181
– volume: 63
  start-page: 157
  issue: 1
  year: 2011
  end-page: 181
  ident: CR1
  article-title: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.110.002857
– volume: 16
  start-page: 339
  issue: 4
  year: 2006
  end-page: 354
  ident: CR15
  article-title: DRAM: efficient adaptive MCMC
  publication-title: Stat Comput
  doi: 10.1007/s11222-006-9438-0
– volume: 42
  start-page: 1141
  issue: 13
  year: 2003
  end-page: 1160
  ident: CR14
  article-title: Clinical pharmacokinetics of atorvastatin
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200342130-00005
– volume: 41
  start-page: 197
  issue: 3
  year: 2014
  end-page: 209
  ident: CR6
  article-title: A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling
  publication-title: J Pharmacokinet Pharmacodyn
  doi: 10.1007/s10928-014-9357-1
– volume: 1
  start-page: 611
  issue: 8
  year: 2002
  end-page: 616
  ident: CR36
  article-title: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance
  publication-title: Mol Cancer Ther
– volume: 354
  start-page: 310
  issue: 3
  year: 2015
  end-page: 315
  ident: CR8
  article-title: Marked alteration of rosuvastatin pharmacokinetics in healthy Chinese with ABCG2 34G>A and 421C>A homozygote or compound heterozygote
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.115.225045
– volume: 25
  start-page: 2553
  issue: 10
  year: 2003
  end-page: 2563
  ident: CR11
  article-title: Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers
  publication-title: Clin Ther
  doi: 10.1016/S0149-2918(03)80316-8
– volume: 10
  start-page: 5889
  issue: 17
  year: 2004
  end-page: 5894
  ident: CR33
  article-title: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0144
– volume: 13
  start-page: 19
  issue: 1
  year: 2003
  end-page: 28
  ident: CR35
  article-title: Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200301000-00004
– volume: 2
  start-page: 41
  year: 2011
  ident: CR28
  article-title: Paraoxonase (PON1 and PON3) polymorphisms: impact on liver expression and atorvastatin-lactone hydrolysis
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2011.00041
– volume: 16
  start-page: 801
  issue: 11
  year: 2006
  end-page: 808
  ident: CR21
  article-title: Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics
  publication-title: Pharmacogenet Genom
  doi: 10.1097/01.fpc.0000230422.50962.91
– volume: 31
  start-page: 735
  issue: 10
  year: 2011
  end-page: 743
  ident: CR5
  article-title: Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men
  publication-title: Clin Drug Investig
  doi: 10.2165/11592480-000000000-00000
– volume: 82
  start-page: 541
  issue: 5
  year: 2007
  end-page: 547
  ident: CR18
  article-title: SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100190
– volume: 33
  start-page: 94
  issue: 1
  year: 2005
  end-page: 101
  ident: CR37
  article-title: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.104.001628
– volume: 28
  start-page: 196
  issue: 3
  year: 2013
  end-page: 202
  ident: CR17
  article-title: Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.DMPK-12-RG-068
– volume: 26
  start-page: 577
  issue: 3
  year: 2013
  end-page: 584
  ident: CR41
  article-title: Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males
  publication-title: Pak J Pharm Sci
– volume: 73
  start-page: 554
  issue: 6
  year: 2003
  end-page: 565
  ident: CR42
  article-title: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(03)00060-2
– volume: 94
  start-page: 37
  issue: 1
  year: 2013
  end-page: 51
  ident: CR2
  article-title: Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2012.221
– volume: 43
  start-page: 23
  issue: 1
  year: 2003
  end-page: 28
  ident: CR4
  article-title: Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270002239702
– volume: 18
  start-page: 424
  issue: 5
  year: 2008
  end-page: 433
  ident: CR26
  article-title: The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15
  publication-title: Pharmacogenet Genom
  doi: 10.1097/FPC.0b013e3282fb02a3
– volume: 95
  start-page: 1238
  issue: 6
  year: 2006
  end-page: 1257
  ident: CR10
  article-title: Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
  publication-title: J Pharm Sci
  doi: 10.1002/jps.20502
– volume: 3
  start-page: e151
  year: 2014
  ident: CR20
  article-title: Toward prospective prediction of pharmacokinetics in OATP1B1 genetic variant populations
  publication-title: CPT Pharmacomet Syst Pharmacol
  doi: 10.1038/psp.2014.50
– volume: 41
  start-page: 24
  issue: 1
  year: 2011
  end-page: 34
  ident: CR25
  article-title: Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors
  publication-title: Xenobiotica
  doi: 10.3109/00498254.2010.523736
– volume: 78
  start-page: 587
  issue: 3
  year: 2014
  end-page: 598
  ident: CR19
  article-title: Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.12377
– volume: 27
  start-page: 106
  issue: 1
  year: 2012
  end-page: 121
  ident: CR32
  article-title: Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.DMPK-11-RV-099
– volume: 29
  start-page: 239
  issue: 2
  year: 1990
  end-page: 243
  ident: CR12
  article-title: Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.1990.tb03626.x
– volume: 62
  start-page: 409
  issue: 6
  year: 2006
  end-page: 415
  ident: CR38
  article-title: Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-006-0123-1
– volume: 43
  start-page: 1045
  issue: 7
  year: 2015
  end-page: 1055
  ident: CR3
  article-title: Ethnic variability in the expression of hepatic drug transporters: absolute quantification by an optimized targeted quantitative proteomic approach
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.063362
– volume: 78
  start-page: 330
  issue: 4
  year: 2005
  end-page: 341
  ident: CR40
  article-title: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2005.06.013
– volume: 17
  start-page: 647
  issue: 8
  year: 2007
  end-page: 656
  ident: CR23
  article-title: Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e3280ef698f
– volume: 80
  start-page: 356
  issue: 4
  year: 2006
  end-page: 366
  ident: CR27
  article-title: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2006.06.010
– volume: 71
  start-page: 341
  issue: 3
  year: 2015
  end-page: 355
  ident: CR30
  article-title: Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-014-1801-z
– volume: 35
  start-page: 705
  issue: 6
  year: 2010
  end-page: 712
  ident: CR31
  article-title: ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations
  publication-title: J Clin Pharm Ther
  doi: 10.1111/j.1365-2710.2009.01127.x
– volume: 109
  start-page: 238
  issue: 2
  year: 2004
  end-page: 246
  ident: CR34
  article-title: Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2
  publication-title: Int J Cancer
  doi: 10.1002/ijc.11669
– volume: 83
  start-page: 251
  issue: 2
  year: 2008
  end-page: 257
  ident: CR43
  article-title: Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100267
– volume: 39
  start-page: 67
  issue: 1
  year: 2012
  end-page: 86
  ident: CR9
  article-title: Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
  publication-title: J Pharmacokinet Pharmacodyn
  doi: 10.1007/s10928-011-9232-2
– volume: 5
  start-page: 703
  issue: 7
  year: 2009
  end-page: 729
  ident: CR22
  article-title: Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
  publication-title: Expert Opin Drug Metab Toxicol
  doi: 10.1517/17425250902976854
– volume: 86
  start-page: 197
  issue: 2
  year: 2009
  end-page: 203
  ident: CR7
  article-title: ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2009.79
– volume: 82
  start-page: 726
  issue: 6
  year: 2007
  end-page: 733
  ident: CR16
  article-title: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100220
– volume: 46
  start-page: 695
  issue: 6
  year: 2011
  end-page: 700
  ident: CR39
  article-title: Effect of OATP1B1 521T>C heterogenesis on pharmacokinetic characteristics of rosuvastatin in Chinese volunteers
  publication-title: Acta Pharm Sin
– volume: 71
  start-page: 329
  issue: 3
  year: 2015
  ident: 568_CR13
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-014-1800-0
– volume: 109
  start-page: 238
  issue: 2
  year: 2004
  ident: 568_CR34
  publication-title: Int J Cancer
  doi: 10.1002/ijc.11669
– volume: 42
  start-page: 1141
  issue: 13
  year: 2003
  ident: 568_CR14
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200342130-00005
– volume: 78
  start-page: 330
  issue: 4
  year: 2005
  ident: 568_CR40
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2005.06.013
– volume: 86
  start-page: 197
  issue: 2
  year: 2009
  ident: 568_CR7
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2009.79
– volume: 3
  start-page: e151
  year: 2014
  ident: 568_CR20
  publication-title: CPT Pharmacomet Syst Pharmacol
  doi: 10.1038/psp.2014.50
– volume: 87
  start-page: 65
  issue: 1
  year: 2010
  ident: 568_CR29
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2009.181
– volume: 43
  start-page: 23
  issue: 1
  year: 2003
  ident: 568_CR4
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270002239702
– volume: 78
  start-page: 587
  issue: 3
  year: 2014
  ident: 568_CR19
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.12377
– volume: 73
  start-page: 554
  issue: 6
  year: 2003
  ident: 568_CR42
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(03)00060-2
– volume: 14
  start-page: 429
  issue: 7
  year: 2004
  ident: 568_CR24
  publication-title: Pharmacogenetics
  doi: 10.1097/01.fpc.0000114750.08559.32
– volume: 94
  start-page: 37
  issue: 1
  year: 2013
  ident: 568_CR2
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2012.221
– volume: 43
  start-page: 1045
  issue: 7
  year: 2015
  ident: 568_CR3
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.063362
– volume: 16
  start-page: 339
  issue: 4
  year: 2006
  ident: 568_CR15
  publication-title: Stat Comput
  doi: 10.1007/s11222-006-9438-0
– volume: 28
  start-page: 196
  issue: 3
  year: 2013
  ident: 568_CR17
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.DMPK-12-RG-068
– volume: 17
  start-page: 647
  issue: 8
  year: 2007
  ident: 568_CR23
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e3280ef698f
– volume: 5
  start-page: 703
  issue: 7
  year: 2009
  ident: 568_CR22
  publication-title: Expert Opin Drug Metab Toxicol
  doi: 10.1517/17425250902976854
– volume: 13
  start-page: 19
  issue: 1
  year: 2003
  ident: 568_CR35
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200301000-00004
– volume: 63
  start-page: 157
  issue: 1
  year: 2011
  ident: 568_CR1
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.110.002857
– volume: 95
  start-page: 1238
  issue: 6
  year: 2006
  ident: 568_CR10
  publication-title: J Pharm Sci
  doi: 10.1002/jps.20502
– volume: 1
  start-page: 611
  issue: 8
  year: 2002
  ident: 568_CR36
  publication-title: Mol Cancer Ther
– volume: 26
  start-page: 577
  issue: 3
  year: 2013
  ident: 568_CR41
  publication-title: Pak J Pharm Sci
– volume: 354
  start-page: 310
  issue: 3
  year: 2015
  ident: 568_CR8
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.115.225045
– volume: 35
  start-page: 705
  issue: 6
  year: 2010
  ident: 568_CR31
  publication-title: J Clin Pharm Ther
  doi: 10.1111/j.1365-2710.2009.01127.x
– volume: 31
  start-page: 735
  issue: 10
  year: 2011
  ident: 568_CR5
  publication-title: Clin Drug Investig
  doi: 10.2165/11592480-000000000-00000
– volume: 29
  start-page: 239
  issue: 2
  year: 1990
  ident: 568_CR12
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.1990.tb03626.x
– volume: 25
  start-page: 2553
  issue: 10
  year: 2003
  ident: 568_CR11
  publication-title: Clin Ther
  doi: 10.1016/S0149-2918(03)80316-8
– volume: 46
  start-page: 695
  issue: 6
  year: 2011
  ident: 568_CR39
  publication-title: Acta Pharm Sin
– volume: 33
  start-page: 94
  issue: 1
  year: 2005
  ident: 568_CR37
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.104.001628
– volume: 41
  start-page: 197
  issue: 3
  year: 2014
  ident: 568_CR6
  publication-title: J Pharmacokinet Pharmacodyn
  doi: 10.1007/s10928-014-9357-1
– volume: 80
  start-page: 356
  issue: 4
  year: 2006
  ident: 568_CR27
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2006.06.010
– volume: 83
  start-page: 251
  issue: 2
  year: 2008
  ident: 568_CR43
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100267
– volume: 71
  start-page: 341
  issue: 3
  year: 2015
  ident: 568_CR30
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-014-1801-z
– volume: 27
  start-page: 106
  issue: 1
  year: 2012
  ident: 568_CR32
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.DMPK-11-RV-099
– volume: 82
  start-page: 541
  issue: 5
  year: 2007
  ident: 568_CR18
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100190
– volume: 2
  start-page: 41
  year: 2011
  ident: 568_CR28
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2011.00041
– volume: 10
  start-page: 5889
  issue: 17
  year: 2004
  ident: 568_CR33
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0144
– volume: 41
  start-page: 24
  issue: 1
  year: 2011
  ident: 568_CR25
  publication-title: Xenobiotica
  doi: 10.3109/00498254.2010.523736
– volume: 16
  start-page: 801
  issue: 11
  year: 2006
  ident: 568_CR21
  publication-title: Pharmacogenet Genom
  doi: 10.1097/01.fpc.0000230422.50962.91
– volume: 62
  start-page: 409
  issue: 6
  year: 2006
  ident: 568_CR38
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-006-0123-1
– volume: 39
  start-page: 67
  issue: 1
  year: 2012
  ident: 568_CR9
  publication-title: J Pharmacokinet Pharmacodyn
  doi: 10.1007/s10928-011-9232-2
– volume: 82
  start-page: 726
  issue: 6
  year: 2007
  ident: 568_CR16
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/sj.clpt.6100220
– volume: 18
  start-page: 424
  issue: 5
  year: 2008
  ident: 568_CR26
  publication-title: Pharmacogenet Genom
  doi: 10.1097/FPC.0b013e3282fb02a3
SSID ssj0008200
Score 2.3667002
Snippet Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is...
Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A...
Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 491
SubjectTerms Asian Continental Ancestry Group - genetics
Atorvastatin - administration & dosage
Atorvastatin - pharmacokinetics
ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics
ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism
Breast cancer
Carbamates - administration & dosage
Carbamates - pharmacokinetics
Computer Simulation
Cultural differences
Drug dosages
European Continental Ancestry Group - genetics
Gene Frequency
Genes
Genotype
Haplotypes
Healthy Volunteers
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - pharmacokinetics
Hypotheses
Internal Medicine
Liver-Specific Organic Anion Transporter 1 - genetics
Liver-Specific Organic Anion Transporter 1 - metabolism
Medicine
Medicine & Public Health
Metabolism
Minority & ethnic groups
Models, Biological
Neoplasm Proteins - genetics
Neoplasm Proteins - metabolism
Original
Original Research Article
Pharmacogenomic Variants
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Phenotype
Piperidines - administration & dosage
Piperidines - pharmacokinetics
Polypeptides
Population genetics
Pravastatin - administration & dosage
Pravastatin - pharmacokinetics
Proteins
Quinolines - administration & dosage
Quinolines - pharmacokinetics
Rosuvastatin Calcium - administration & dosage
Rosuvastatin Calcium - pharmacokinetics
Studies
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9tAEB5a59JL6btq0jKFkkMbUb131UuRjU0oJBXBKbkJaSURUyOntnPwf8uP68yuHrihOQppJS0zOzPf7sw3AJ-UCIuKK3M9oSI7iEppS4oDbCWLXNal5we6TefZeXR6Gfy4Cq_aDbdNm1bZ2URtqMuV4j3yrwRNYo_Nqfv95o_NXaP4dLVtofEYDsgEy3AEB-PpeXrR22Lyb44p1SHIRbrWnWty8Rwhp4jTEoRNQYC0xb5nuhdu3s-a_OfoVHuk2TN42oaSmBjZP4dHVfMCjlPDRb07wflQWrU5wWNMB5bq3Uu44-w70x4Cp9vrZqHwF-FmQ9u9w1WNA-_5Gtm-aB7b_i2_KTzlN-OiQVPLtMOEKzIxb0qc5NxMja9oJG_1bJB3fDFZLsnP4WxtMrgJpvOXfibz1B27euR4cpF-wwTPKq5J1jTSyA3buGweOwqVV3A5m84np3bbysFWgXC2Nnk9nVBKrjEOopxRn-floZSRKPIgVi7HPcIX3ApbFkFeEQwL4pocSRn6YeX4r2HUrJrqLaCjShF7KioKRdGUJrNxo7II6oqgn6prC5xOjJlqec653cYy6xmateQzknzGks-EBZ_7ITeG5OOhh4863cja9b7JBu204GN_m1YqH7_kTbW63WTMpMfw1g0teGNUqf8a1wf7hG0tEHtK1j_ALOD7d5rFtWYDJ7wXydiz4EunjsNv_XcS7x6exCE8ocBQmgylIxht17fVewq-tsWHdoX9BbFsLFM
  priority: 102
  providerName: ProQuest
Title Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis
URI https://link.springer.com/article/10.1007/s40262-017-0568-7
https://www.ncbi.nlm.nih.gov/pubmed/28653144
https://www.proquest.com/docview/2109280121
https://www.proquest.com/docview/1914289915
https://pubmed.ncbi.nlm.nih.gov/PMC5856892
Volume 57
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9tAEB6aBEovpU0fUZuaKZQc2ojquSv1JhmbULBrglN8E9JKIqZGLpZz8H_rj-uMVpJx0hZ6Mkb7sNGsZj7NfN8AfFDSzwpm5jpSCdMTeWAGFAeYKsjSoMwd12vadE6m4urG-7rwF61YNHNh7uXvP9eEbwQXD0iTXHVgyiM48VlmjPOyYtg_dMmRWZqTQ9iKjKpLYP5piUMX9CCufFgeeS9H2rie8TN42saMGOmb_BweFdUpPJ60WfFTuJhp_endJc73dKr6Ei9wtlem3r2AX1xxp1tC4Gh7Wy0VfiesrKW6d7guca91vkF-pjTatf0qP2g7XhmXFWr-0g4jZmFiWuU4TLmBGn-jmfx6p0Z-y4vRakW-DccbXbVN0Jx3-hbNZ3ZsNzPj4fXsC0Y4KZiH3EhHIzdpY6o8drIpL-FmPJoPr8y2fYOpPGltTfJ0TREpucPQEykjPcdJ_SAQMku9UNkc60hXcvvrIPPSgqCXF5bkPHLf9QvLfQXH1boqzgAtlcvQUSLLFEVQjYCNLfLMKwuCe6osDbC6O5qoVtucW2yskl6VuTGChIwgYSNIpAEf-yk_tbDHvwafd2aStGe8Tggshw47eNuA9_1lOp2cckmrYn1XJ6yex5DW9g14ra2q3405wS7hWQPkgb31A1j5-_BKtbxtFMAJ44kgdAz41Fnm_mf99U-8-a_Rb-EJxYaBLlI6h-Pt5q54R_HXNhvAkVzIAZxE4zie0mc8ms6uB815_A0sGCq3
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEB6V9gAXxD-GAoMEPUAtYsf22kgIOSFRSpsQVWnVm7HXazUickqcCuWleAIejhlvbCtU9NZjZO9urJmdmW935huAN1K4ieLKXFtIz3S81Dd9igNM6Sexn6V22ynbdA5H3uDE-Xrmnm3B76oWhtMqK5tYGup0LvmM_ANBk8Bmc2p9vvhpctcovl2tWmhotThUq18E2YpPB19Ivm9tu9-bdAfmuquAKR3RWppkgMvcRrLSgePFDEBsO3Z93xNJ7ATSYhcs2oK7MvuJEytCBE6QkU1L3barWm2a9xbsUJgR0C7a6fRG4-Pa9pM_benSIIJ4pNvVPSoX6xFS8zgNQpi0uG-KTU94Jby9mqX5z1Vt6QH79-DuOnTFUOvafdhS-QPYG2vu69U-TppSrmIf93DcsGKvHsIfzvbT7SiwtzzPpxJPCadrmvAVzjNseNYXyPas5M2tZ_lB4TDPjNMcde3UCkOuAMU4T7Ebc_M2_kUj-WipQD5hxnA2I7-K_YXOGJ-qglf6Fk7GVscqR3a6x-OPGOJQcQ10SVuN3CCOy_Sxomx5BCc3IuTHsJ3Pc_UUsCVTEdjSSxJJ0VtJnmN5aeJkiqCmzDIDWpUYI7nmVef2HrOoZoQuJR-R5COWfCQMeFcPudCkIte9vFvpRrS2L0XU7AYDXtePyTLwdU-cq_llETFzH8NpyzXgiValejWuR24TljZAbChZ_QKzjm8-yafnJfs44UvPD2wD3lfq2Pyt_37Es-s_4hXcHkyGR9HRwejwOdyhoNTX2VG7sL1cXKoXFPgtk5fr3Ybw_aY3-F-EKmUa
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9NADLdGJyFeEN9kDDAS7AEWrUmT3AUJobZrtTFWoqlDewvJ5aJVq9LRdEL91xB_HHa-qjKxtz1Wyd01ss_2787-GeCtEm6suTLXFsozHS-RpqQ4wFQyjmSa2B2naNN5PPIOTp0vZ-7ZBvyua2E4rbK2iYWhTmaKz8j3CJr4NptTay-t0iKC_eHny58md5Dim9a6nUapIkd6-YvgW_7pcJ9k_c62h4Nx_8CsOgyYyhHthUnGuMhzJIvtO17EYMS2I1dKT8SR4yuL3bHoCO7QLGMn0oQOHD8l-5a4HVe3OzTvHdgU5BVlCzZ7g1Fw0vgB8q3tskyI4B7peX2nyoV7hNo8TokQJi0uTbHuFa-FutczNv-5ti284fAB3K_CWOyWevcQNnT2CHaCkgd7uYvjVVlXvos7GKwYspeP4Q9n_pWtKXCwOM8mCr8TZi8pw5c4S3HFuT5Htm0Fh24zywWFxjwzTjIs66iW2OVqUIyyBPsRN3LjXzSSj5ly5NNm7E6n5GNxOC-zxyc655W-dceB1bOKkb3-SfARu3isuR66oLBGbhbHJftY07c8gdNbEfJTaGWzTD8HbKtE-Lby4lhRJFcQ6VheEjupJtip0tSAdi3GUFUc69zqYxo27NCF5EOSfMiSD4UB75shlyXByE0vb9e6EVa2Jg9XO8OAN81jshJ89RNlenaVh8zix9Dacg14VqpSsxrXJncIVxsg1pSseYEZyNefZJPzgomcsKYnfduAD7U6rv7Wfz9i6-aPeA13aWOHXw9HRy_gHsWnskyU2obWYn6lX1IMuIhfVZsN4cdt7--_W1lpRg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Explaining+Ethnic+Variability+of+Transporter+Substrate+Pharmacokinetics+in+Healthy+Asian+and+Caucasian+Subjects+with+Allele+Frequencies+of+OATP1B1+and+BCRP%3A+A+Mechanistic+Modeling+Analysis&rft.jtitle=Clinical+pharmacokinetics&rft.au=Li%2C+Rui&rft.au=Barton%2C+Hugh+A.&rft.date=2018-04-01&rft.pub=Springer+International+Publishing&rft.issn=0312-5963&rft.eissn=1179-1926&rft.volume=57&rft.issue=4&rft.spage=491&rft.epage=503&rft_id=info:doi/10.1007%2Fs40262-017-0568-7&rft.externalDocID=10_1007_s40262_017_0568_7
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0312-5963&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0312-5963&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0312-5963&client=summon